The Client

Norgine was a family owned specialty pharmaceutical company. Following the acquisition of a majority stake in the company by Goldman Sachs, the company refocused as a much more active platform for acquisitions, in-licencing and launch execution in Europe.

The Situation

Following the Goldman Sachs investment, the CFO role shifted from a “rigorous steward” archetype to a “commercially fluent, sponsor and deal capable finance leader” archetype. Norgine’s Board agreed with RSA’s recommendation that the company put in place an Interim with the “right” archetype to come into the business immediately whilst an executive search was underway.

The Outcome

Within two weeks, RSA had identified 12 credible candidates. Norgine interviewed a short list and a few days later an offer was made to a suitable candidate.

The Interim CFO moved into position for an initial period of six months but agreed to stay in post for an additional three months so that they could complete a detailed handover with the appointed full-time CFO. They supported the company’s activities during a critical “integration and acceleration phase” and ensured continuity through the handover period.

Client & Candidate Testimonial

"I enjoyed working with The RSA Group team on an Interim CFO assignment at a multi-billion valued PE owned Specialty Pharma Business. From the outset, it was clear that they understood the needs of both the client and stakeholders and matched them effectively with the consultant’s expertise. Their experience and solution-oriented approach made the contracting and administrative process seamless. Combined with regular communication and feedback throughout the assignment, this helped ensure a successful outcome for all parties. I would thoroughly recommend The RSA Group." — Richard Millbank, Interim CFO